Package: BOIN
Type: Package
Title: Bayesian Optimal INterval (BOIN) Design for Single-Agent and
Drug- Combination Phase I Clinical Trials
Version: 2.7.0
Date: 2020-09-28
Author: Ying Yuan and Suyu Liu
Maintainer: Ying Yuan <yyuan@mdanderson.org>
Imports: Iso
Description: The Bayesian optimal interval (BOIN) design is a novel phase I
clinical trial design for finding the maximum tolerated dose (MTD). It can be
used to design both single-agent and drug-combination trials. The BOIN design
is motivated by the top priority and concern of clinicians when testing a new
drug, which is to effectively treat patients and minimize the chance of exposing
them to subtherapeutic or overly toxic doses. The prominent advantage of the
BOIN design is that it achieves simplicity and superior performance at the same
time. The BOIN design is algorithm-based and can be implemented in a simple
way similar to the traditional 3+3 design. The BOIN design yields an average
performance that is comparable to that of the continual reassessment method
(CRM, one of the best model-based designs) in terms of selecting the MTD, but
has a substantially lower risk of assigning patients to subtherapeutic or overly
toxic doses. For tutorial, please check Yan et al. (2020) <doi:10.18637/jss.v094.i13>.
License: GPL-2
RoxygenNote: 7.1.0
Encoding: UTF-8
Packaged: 2020-09-28 18:24:59 UTC; jianga
NeedsCompilation: no
Repository: CRAN
Date/Publication: 2020-09-29 08:30:05 UTC

Package: BOIN
Type: Package
Title: Bayesian Optimal INterval (BOIN) Design for Single-Agent and
Drug- Combination Phase I Clinical Trials
Version: 2.7.1
Date: 2020-11-19
Author: Ying Yuan and Suyu Liu
Maintainer: Ying Yuan <yyuan@mdanderson.org>
Imports: Iso
Description: The Bayesian optimal interval (BOIN) design is a novel phase I
clinical trial design for finding the maximum tolerated dose (MTD). It can be
used to design both single-agent and drug-combination trials. The BOIN design
is motivated by the top priority and concern of clinicians when testing a new
drug, which is to effectively treat patients and minimize the chance of exposing
them to subtherapeutic or overly toxic doses. The prominent advantage of the
BOIN design is that it achieves simplicity and superior performance at the same
time. The BOIN design is algorithm-based and can be implemented in a simple
way similar to the traditional 3+3 design. The BOIN design yields an average
performance that is comparable to that of the continual reassessment method
(CRM, one of the best model-based designs) in terms of selecting the MTD, but
has a substantially lower risk of assigning patients to subtherapeutic or overly
toxic doses. For tutorial, please check Yan et al. (2020) <doi:10.18637/jss.v094.i13>.
License: GPL-2
RoxygenNote: 7.1.1
Encoding: UTF-8
Packaged: 2020-11-19 20:55:25 UTC; jianga
NeedsCompilation: no
Repository: CRAN
Date/Publication: 2020-11-19 22:20:02 UTC